CURE Pharmaceutical has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s pharmaceutical groups specialized in medicinal cannabis products. The agreement grants ReLeaf Europe exclusive access to CURE’s encapsulation technology for certain oral and topical cannabis products in the Netherlands.
According to market research, Europe is one of the world’s largest medical cannabis markets due to various governments’ approval for medicinal purposes.
“ReLeaf Europe is one of the few pharmacy providers of pharmaceutical-grade medicinal cannabis oils in Europe and an ideal partner for our first step into the European market because of its commitment to establishing clinical evidence and following EU GMP and GDP standards,” said Jessica Rousset, COO of CURE. “Through this agreement, we will roll out our powered by CURE strategy that includes exclusive licensing relationships to build global market share.”
ReLeaf Europe is tackling the largest market in the world for cannabis by establishing a foothold in Holland, a market estimated to reach $2.6B by 2028.
“We are standard-bearers in clinical cannabis care in Europe and CURE shares our values in its science and manufacturing practices in seeking the highest of quality standards,” said Jesse Kuijper, CEO of ReLeaf Europe. “This collaboration will help accelerate our market presence through highly differentiated products.”
CURE will power several ReLeaf Europe products, including one sublingual tincture and two topical creams to be launched in 2020.